Docstoc

Cures Faster

Document Sample
Cures Faster Powered By Docstoc
					     Cures
Faster
The Center for Accelerating Medical Solutions


                                                2010 PROGRESS REPORT
02   Letter from the Executive Director
04   Who We Are
05   What We Do

OUR PROGRAM AREAS

06   Collaboration
10   Patients
12   Process and Policy
16   Capital

18   Our Voice
20   Get Involved
    DEAR FRIENDS of FasterCures,

    2010 was a turning point for the medical research community.
    We marked the 10th anniversary of the decoding of the
    human genome and yet, its potential remains largely
    untapped. We saw much attention focused on access to
    healthcare and its costs, and yet for too many one question
    remained unanswered — where are my treatments and cures?

    With fiscal budgets still strained, we continued to look
    even more closely at the return on our investment — and
    the 21 new therapies that reached the market in 2010 just
    did not seem enough return for our investment in
    scientific discovery.

    Challenges not withstanding, we saw unprecedented,
    and at times renewed, commitment from all stakeholders
    to transform, modernize, and improve the medical
    research system.




2
In 2010, FasterCures implemented programs and created
opportunities that:

•   CONVENED NONTRADITIONAL ALLIES             to explore vitally needed
    collaborations.
•   CONNECTED BEST PRACTICES TO POLICIES AND PROCESSES to spur
    broad adoption of forward-thinking approaches.
•   CATALYZED AN OUTCOMES-DRIVEN ENTERPRISE  by speaking
    truth to power and challenging the system to deliver the
    best possible outcomes for every patient.

We strive for a future where each medical research sector
is operating at peak performance. It is our vision to create
a research culture driven by collaboration and designed to
meet and anticipate the needs of patients.

I am pleased to share the highlights of our year and I ask
you to join us in our mission to find cures — faster. Your
support makes it possible for us to be that strong and
independent voice, and to engage the right people and
organizations around the right solutions at the right time.

             Sincerely,


             Margaret Anderson
             Executive Director, FasterCures




                                                                           3
CLEARTHEPATHTOPROGRESS


                         WHO WE ARE
                         FasterCures is not just our name — it’s our mission.
                         We are an “action tank” that works to improve the
                         medical research system — so that we can speed up
                         the time it takes to get important new medicines
                         from discovery to patients.
                         Despite the human and financial capital flowing through our healthcare
                         system, the fact remains that more than 100 million Americans suffer from
                         cancer, Alzheimer's disease, diabetes, Parkinson's disease, heart disease,
                         and others for which there are still no cures — and, in many cases, few
                         meaningful treatment options.

                         We’ll all be patients at some point. We have to act now and act smartly —
                         because patients are dying every day waiting for treatments and cures.


                         Our mission is to accelerate the progress of discovery and development of
                         new medical solutions for deadly and debilitating diseases. We are nimble
                         and independent, a “safe place” for key stakeholders of the medical research
                         enterprise to come together and get things done.


                         FasterCures, the Milken Institute’s Center for Accelerating Medical
                         Solutions, is nonpartisan and not affiliated with interest groups.




4
WHATWE DO
Be it lack of medical breakthroughs, limited resources, or
restrictive policies that are stalling progress, patients are
paying the price in life or death consequences.
Is this acceptable?
At FasterCures, we work to clear the path to faster progress by educating stakeholders
about the barriers, and by overcoming them through action.

We start and end everything we do with the patient in mind. For the medical research
system to work, it has to be patient-focused, and patient-driven. So we work alongside
patient advocates, researchers, investors, policymakers, and other leaders in medical
research and development to:

•   STIMULATE innovative COLLABORATIONS across all sectors — academia, government,
    industry, investors, and nonprofits.
•   INCREASE PATIENT ENGAGEMENT in research and optimize use of patient data.
•   IMPROVE research PROCESS & POLICY to support efficient development and approval
    of new therapies.
•   FACILITATE greater access and more strategic allocation of CAPITAL to support
    results-driven medical research.

We have a number of high-impact programs that are laser-focused on improving the
medical research system because we firmly believe that each life saved by preventing
disease and developing new cures is priceless.




                                                                                         5
COLLABORATION


                Getting new medicines to patients takes too long and costs
                too much — medical research in our country has stalled.
                And that has to change — that’s where FasterCures comes in.
                Expediting cures requires collaboration — across sectors,
                disciplines, and areas of expertise.


                                    “FasterCures has a unique ability to bring together people from all
                                    the various sectors of medical research, gather disparate interests,
                                    and develop common solutions to address similar challenges.”
                                      DAVID BALTIMORE, PH.D.
                                      Nobel Laureate and FasterCures Board Member




                THE RESEARCH ACCELERATION AND INNOVATION NETWORK (TRAIN)
                Recognizing that a collective approach is needed to successfully address the barriers
                to innovation, FasterCures created TRAIN and brought together dozens of disease
                research organizations with collaborative and results–oriented research methods. In
                many cases, these groups, also known as venture philanthropies, were created by patients
                and their families, and are motivated solely by the true bottom line: finding a cure.

                We amplify TRAIN’s best practices and tell the story of these “entrepreneurs for cures”
                in an effort to bring their sense of urgency to the rest of the medical research community.
                Everyone can benefit from the lessons they’ve learned.




6
ENTREPRENEURS FOR CURES ARE
       MOTIVATED SOLELY BY THE TRUE
    BOTTOM LINE: FINDING A CURE.
    IN 2010, FASTERCURES …
    •   Expedited disease research with the launch of TRAIN Central Station. This first-of-
        its-kind public portal allows real-time sharing of valuable information and tools
        for and from venture philanthropies. It saves time by preventing duplication of efforts,
        and applying processes already proven to be effective. Other nonprofits, industry,
        academia, policymakers, and media have turned to this resource for the latest patient-
        driven trends, tools, and techniques.
    •   Informed policymakers about the venture philanthropy model at a briefing on Capitol Hill
        in partnership with the Cystic Fibrosis Foundation. Policymakers and influencers learned
        about how this model — that features industry partnerships and a robust patient
        registry — has fast-tracked the development of therapies that otherwise would not have
        been pursued by industry. The standing room-only event featured National Institutes
        of Health Director Francis Collins, M.D.
    •   Educated stakeholders about hot-button issues through solutions-focused Webinars.
        The TRAIN Webinar series offered a highly-efficient way to stimulate discussion about
        issues and efforts key to moving solutions forward. For instance, one Webinar focused
        on a program about “cures in the cupboard,” addressing an often cited need to find
        new purposes for industry’s discontinued compounds.

    MOVING FORWARD
    FasterCures will continue to identify and promote models of innovation and collaboration
    in medical research because by focusing on critical elements of success, we are able to
    pursue a better informed, more sustainable path to developing new cures for disease.




                                      T RAI N
                                           CATALYZING INNOVATIVE
                                      APPROACHES TO DISEASE RESEARCH.




                                                                                                   7
                  PARTNERING FOR CURES IS
                WHERE COLLABORATION HAPPENS AND
                     IDEAS ARE SHARED OPENLY
                PARTNERING FOR CURES
                Getting to faster cures requires academia, government, industry, investors, and nonprofits
                to work together. Until FasterCures created the Partnering for Cures meeting in 2009,
                it was nearly impossible for many major players in research to easily find each other and
                collaborate in a meaningful way. This unique event is set apart by the diversity of its
                participants, the scope and quality of the dialogue, and the networking opportunities
                structured to make collaboration happen.

                IN 2010, FASTERCURES…
                •   Spurred collaboration across sectors for the second year in a row as hundreds of
                    leaders actively engaged in the dynamic dialogue and partnership opportunities.
                    Our measures for its ultimate success are the numbers of lives saved because new
                    medical solutions were developed. Some outcomes include:
COLLABORATION




                    •   An investment partnership between a nonprofit and a biotech company that allowed
                        for early stage research on a rare cancer drug candidate to move forward.
                    •   A transformative partnership between two nonprofits to pool and analyze large
                        clinical and molecular datasets to better understand disease.
                    •   A joint program between a pharmaceutical company and nonprofit research
                        foundation to support novel research in mental health that resulted in joint grants
                        for young investigators.

                MOVING FORWARD
                Through Partnering for Cures, FasterCures will continue to bring non-traditional
                allies together to collaborate and create new business approaches vital to turning
                breakthroughs into solutions that can save and improve lives.




                                                        Partnering for Cures features an esteemed speaker roster;
                                                        peer-reviewed presentations on real-world collaborations; a highly
                                                        sought–after customized partnering system to arrange one-on-one
                                                        meetings; and other strategic networking opportunities.




8
BY THE NUMBERS                                      THE BOTTOM LINE


> 800 PARTICIPANTS                                  ACCELERATING MEDICAL PROGRESS
> 700 ORGANIZATIONS ACROSS SECTORS                  BY FACILITATING TANGIBLE, STRATEGIC
> 83 SPEAKERS                                       COLLABORATIONS ACROSS SECTORS.
> 16 PANEL AND PLENARY SESSIONS
> 31 INNOVATOR PRESENTATIONS
> 25 EXPERTS PROVIDING FREE CONSULTATIONS
> 600 PARTNERING MEETINGS




                                            “By getting organizations and companies that are used to
                                            competing to instead work together, FasterCures hopes to
                                            break down walls that may slow the achievement of medical
                                            discoveries that could save lives."
                                               CHRONICLE OF PHILANTHROPY




                                                                                                        9
           MAKING PATIENT INFORMATION
             AVAILABLE TO RESEARCHERS IN A
           MEANINGFUL WAY.
PATIENTS



              For the medical research system to work, it has to be
              patient-focused and patient-driven.

              PATIENTS HELPING DOCTORS (PHD)
              The Patients Helping Doctors program anchors everything we do at FasterCures.
              We cannot conquer disease without engaging patients. We focus our efforts on
              unlocking patient information — medical records, biological material such as
              tissue, blood, and DNA, and our biology as observed in clinical trials — and
              making these available to clinical researchers in a meaningful way.




10
                                                       “FasterCures is key for the two things that I hold as
                                                       important in advancing progress – patient advocacy
                                                       and patient participation in research.”
                                                        ANTHONY FAUCI, M.D.
                                                        Director, National Institute of Allergy and Infectious Diseases




IN 2010, FASTERCURES …
•     Worked to ensure research was part of health information technology (health IT).
      When health IT emerged as a national priority more than five years ago, FasterCures
      was the first to call for combining clinical data with research goals, with the release
      of our 2005 report, Think Research. Now, as the healthcare system joins the digital
      age, we continue to be a leading force to ensure health IT can be used to both
      improve care delivery and advance clinical research.

      We refreshed our Think Research analysis with what has — and has not — evolved
      in the national health IT framework. We identified steps necessary to quickly allow
      those involved in the cure enterprise to join those in the care delivery system in the
      health IT superhighway. This will lead to earlier and better diagnosis and more
      effective prevention strategies and cures.

MOVING FORWARD
FasterCures will continue to build a culture of participation in research where patients
and healthy volunteers understand the fundamental value they bring to clinical research.
In fighting disease, patience is not a virtue — patients are. Until we put the patient at the
center of medical research, progress will continue to stall.




From Congressional briefings to panels at the Milken
Institute Global Conference, FasterCures continued
to deliver a strong and consistent message: ensure
research priorities align with patients’ needs.




                                                                                                                          11
PROCESSANDPOLICY


                   A 21st Century bullet train on 19th Century steam engine
                   tracks can only go so fast. But that’s the system we have
                   in place for medical research.

                   Some of the most forward-thinking medical innovations
                   are being held back by antiquated bureaucratic and
                   regulatory inefficiencies.



                   SCIENCE AND PROGRESS AT THE FDA
                   FasterCures has made it a policy priority to advocate for a well-funded FDA —
                   an agency that regulates 25 percent of every consumer dollar, and is a critical
                   component to bringing safe and effective medical solutions to patients. We also
                   work to ensure that regulatory policies and scientific expertise are in place to
                   keep pace with advances in medicine and research technology.




12
IT’S NOT THE TRAIN, IT’S THE TRACKS.
   IN 2010, FASTERCURES …
   •   Advocated for greater support for the FDA, working alongside partners at the Alliance
       for a Stronger FDA, to ensure support for greater resources at the agency so that it
       can have the capacity and financial resources necessary to meet 21st Century demands.
       Efforts included engaging in meaningful discussions with key legislative staff, editorial
       boards, the White House Domestic Policy Council, Office of Management and Budget,
       and other decision-makers and influencers.

       We saw results. For FY 2010, the FDA received a 15 percent increase, bringing its total
       budget to $2.3 billion. These additional resources will allow FDA to bolster its expertise
       to better meet the demands that scientific discoveries will create.

   •   Educated policymakers and other stakeholders about the latest regulatory developments.
       We did this by featuring FDA leadership in front of a wide range of audiences at
       Partnering for Cures and on Capitol Hill.

       •   FDA Commissioner Margaret Hamburg, M.D., and Center for Drug Evaluation
           and Research Director Janet Woodcock, M.D., chose Partnering for Cures as the
           venue to present the agency’s draft guidance for pursuing combination therapies.
           This move provides a roadmap for scientists working on unapproved therapies
           that need to work in tandem to be most effective.
       •   We also partnered with
           Friends of Cancer Research
           to inform key members of
           Congress about FDA’s
           efforts to boost its regulatory
           science capacity. The
           agency needs the expertise
           to review exciting medical
           innovations and make them
           available to patients who
           need them most.

   MOVING FORWARD
   FDA will continue to be a
   FasterCures strategic priority as we develop programs           We focus our efforts on ensuring federal
                                                                   policies and processes exist to pave the
   designed to improve our regulatory process. An effective        path between a breakthrough idea and a
   regulatory system is vital to bringing innovation from          medical solution.

   the research community to patients.




                                                                                                              13
     DEMONSTRATED THE CRITICAL VALUE
           OF TRANSLATIONAL RESEARCH IN
     THE SEARCH FOR CURES
         TRANSLATIONAL RESEARCH
         Our national investment in basic science has produced discoveries that now need
         translation. The fact is that many basic discoveries barely get to start the journey
         down the therapeutic development pipeline. They get stuck in an ever-widening gap
         in funding and support for translational research — research that moves basic science
         down the path toward treatments. That gap is the proverbial "Valley of Death.”

         IN 2010, FASTERCURES…
         •   Defined translational research challenges and focused on solutions through our
             influential white paper. FasterCures published Crossing Over the Valley of Death, the
             first comprehensive report that catalogued the challenges in translational research,
             articulated real-world case studies that demonstrated the critical value of this phase
             in the therapeutic development process, and pointed the way toward solutions.

         •   Engaged innovators in bridging the Valley. At the FasterCures-Esquire Annual
             Leadership Forum, a group of thought leaders and innovators from large
             pharmaceutical companies, small biotechnology companies, venture capital funds,
             universities, and nonprofit foundations discussed some novel and collaborative
             approaches to commercialization, and developed a robust menu of vital action
             items to bridging the void between basic and
             clinical research.

         •   Advanced policies that foster translation at the
             National Institutes of Health. We are seeing NIH
             begin to refocus its commitment to translational
             research in response to Americans asking for better
             return on their tax dollars in the form of improved
                                                                             Crossing Over the Valley of Death
             health and cures for disease.




                                                                              translational research
                                                                                                                 16




14
                                                                                           PROCESSANDPOLICY
FasterCures made progress on a number of fronts:

  •   NIH Clinical Center opens its doors to external researchers. FasterCures has
      been a vocal advocate for maximizing the potential of our nation’s research
      crown jewel, the NIH Clinical Center which was underutilized and open only
      to NIH scientists. When the board that advises the NIH director considered
      opening the Center to external scientists, FasterCures galvanized 86 other
      patient advocacy groups within 48 hours, and led an effort to show support
      for expanding access to this facility. Six months later, the Clinical Center
      opened its doors to external investigators. This move is a major boost for
      research teams nationwide who otherwise would not have had access to these
      exceptional resources.


        Fully utilizing the NIH Clinical Center was one of the recommendations that
        FasterCures had put forward in 2008 through its blue-ribbon task force focused
        on the NIH Intramural Research Program led by Nobel Laureate and FasterCures
        board member Dr. David Baltimore. In fact, of the five recommendations the task
        force presented, three have been acted on, with outcomes that will save lives by
        shortening the time it takes to turn breakthroughs into medical solutions.


  •   Cures Acceleration Network (CAN) garners support of patient groups. FasterCures
      educated research stakeholders about this important provision in the Patient
      Protection and Affordable Care Act (health reform law) through a forum in
      partnership with Parkinson’s Action Network. CAN was designed to provide
      NIH with new funding mechanisms that would accelerate the development of
      high-need cures. Throughout the year, FasterCures played an important role
      in educating and rallying the patient advocacy community to advocate for
      support for CAN.

MOVING FORWARD
FasterCures will continue to play a unique role by brokering input from patient-driven
disease research organizations — and possibly other stakeholders — into the process
of defining and implementing major translational research efforts across all sectors.




                                                                                                              15
CAPITAL


          HIGH-RISK, LONG-TERM
                INVESTMENTS ARE NEEDED TO
          ADVANCE MEDICAL INNOVATION.
          By investing in our own health, we can solidify our
          position as Jupiter, the largest planet.

          MEDICAL PHILANTHROPY PORTFOLIO
          Philanthropists have a unique, powerful role in funding high-risk, high-
          reward research that is often ignored by the government, venture capitalists,
          and industry. Our medical philanthropy program helps to facilitate targeted
          giving that can move a field of research forward.




18
                                        “Improved public health translates directly into greater
                                        national productivity, which underpins all economic
                                        growth. So let's get our priorities straight. America's
                                        economy used to be the sun—the gravitational center—
                                        in the "solar system" of leading nations. In the future,
                                        we'll no longer be the sun. But by investing in our own
                                        health, we can help solidify our position as Jupiter,
                                        the largest planet.”
                                           MICHAEL MILKEN, Wall Street Journal Op-Ed




IN 2010, FASTERCURES…
•   Created an objective way to evaluate philanthropic impact. FasterCures’ experience
    and investment in the Philanthropy Advisory Service pilot project yielded in-depth
    insights into nonprofit organizations seeking philanthropic support. We took this
    knowledge and created an evaluation tool to help identify effective organizations.
    This presented us with a way to objectively help philanthropists looking to make an
    impact, and organizations trying to improve their effectiveness.

•   Built a toolkit for high-impact medical philanthropy. We developed a series of tools
    to help philanthropists make better decisions. Already, wealth managers and
    philanthropic advisors are using these resources to advise a broad range
    of clients.

    •   Getting Started: The Medical Research and
        Development (R&D)Primer simplifies the complex
        R&D paradigm and identifies key research
                                                                          givingsmarter
        players. This Primer outlines the steps needed                    Building a High-Impact Medical Philanthropy Portfolio




        to translate advance scientific breakthroughs
        into viable therapies.

    •   Giving Smarter: Building a High Impact Medical
        Philanthropy Portfolio provides donors with a
        framework for evaluating nonprofits to ensure
                                                                                               gettingstarted
        their philanthropy is yielding returns that could                                            The Medical Research and Development Primer




        improve and save lives.                                                                                     Cures
                                                                                                               Faster




MOVING FORWARD
FasterCures will continue to ensure private capital is wisely directed to advance medical
progress. We will work with philanthropic partners to better allocate charitable research
funds to where they are most needed. And we will work with experts to direct funding to
the early-stage, high-risk research needed to further medical innovation.




                                                                                                                                                   17
TRUTHTOPOWER



               OURVOICE
                FasterCures is pushing to create a new mindset in our
                medical research infrastructure so that diverse and
                important stakeholders can share their visionary
                thinking openly, work together, and be driven by what
                patients need.




18
CREATE A NEW MINDSET
IN 2010, FASTERCURES…
•       Drew attention to challenges and spotlighted progress in medical research.
        We turned to our social media vehicles — FasterCures blog, Facebook, and
        Twitter — to engage and inform a diverse range of audiences, in real-time,
        about important developments that stand in the way of medical progress or
        propel it forward. Here are notable excerpts from the FasterCures blog:




“   “Opportunities to change the trajectory of medical research across sectors and for
    all diseases do not come often.” A CRITICAL NEED FOR CURES ACCELERATION, JULY 6, 2010

    “We need policy that allows the research to proceed, with federal dollars and with
    appropriate oversight.” WHY IT'S TIME FOR CONGRESS TO WRITE NEW STEM CELL LEGISLATION,
    AUGUST 30, 2010

    “In search of a-ha moments, what I found were some reminders of just how important
    it is to get the basics right.” RESEARCH'S ALL ABUZZ ABOUT COLLABORATION AND
    COMMUNICATION, MARCH 15, 2010

    “While experiences differ, many of the funding challenges are strikingly similar,




                                                                                         ”
    and there is a need for more intermediaries to help bridge gaps and address market
    constraints.” ACCESSING "SMART MONEY" FOR MEDICAL INNOVATIONS, APRIL 26, 2010



•       Ensured that patient outcomes were accounted for in policy creation. We took
        every opportunity — through testimonies and commentary — to make sure
        federal policies that could impact patients’ lives actually took patients into
        consideration from the get-go. These included:
    •    Commented on proposed changes to the NIH’s conflict-of-interest rules,
         noting that rules need to also consider “confluences of interest”
    •    Called for new data exchange standards that support clinical research to
         be included in the Electronic Health Record Incentive Program Proposed Rule
    •    Shared recommendations from the FasterCures Intramural Research Program
         Task Force with the President’s Council of Advisors on Science and Technology




                                                                                             19
            CONNECT
TO         GET THE LATEST MEDICAL
               RESEARCH TRENDS

                      GETINVOLVED
                    Cures.org
               Faster
               Visit us online and get the latest FasterCures information, publications,
               podcasts, video clips, and other multimedia resources.

                   Brief
               Smart
               Stay informed, get relevant, up-to-date news stories in biomedical
               research delivered to your inbox twice-weekly.

                    CuresBlog
               Faster
               Talk to us. Respond and comment on our blogs about the issues,
               trends, and findings that impact medical research and discovery.
FOLLOWUS




                f
               Find and follow us on Facebook and Twitter – @fastercures – and get
               real-time updates on FasterCures activities, events, and resources and
               medical research news.




20
•   HELP US facilitate outcomes-oriented collaboration.
•   TAKE PART in programs designed to engage patients in research.
•   GET INVOLVED in efforts that will maximize smart R&D investments.
•   SUPPORT our efforts to ensure policies and processes promote progress.
•   INVEST in our mission with a gift to FasterCures.




JOINUS                   ACCELERATE MEDICAL PROGRESS
     Cures
Faster
The Center for Accelerating Medical Solutions


1101 New York Avenue, NW, Suite 620, Washington, DC 20005 / 202-336-8900 / www.FasterCures.org
FasterCures, a center of the Milken Institute, is nonprofit, nonpartisan, and independent of interest groups.

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:4
posted:12/8/2011
language:
pages:24